Climb Bio (CLYM) Capital Expenditures (2025)
Climb Bio (CLYM) reported Capital Expenditures of $109000.0 for Q3 2025.
Climb Bio (CLYM) Capital Expenditures (2025) Analysis & Trends
Climb Bio has reported Capital Expenditures for 1 years, with the latest figure at $109000.0 in Q3 2025.
- For the quarter ending Q3 2025, Capital Expenditures changed N/A year-over-year to $109000.0; the trailing twelve-month figure through Dec 2025 stood at $109000.0 (changed N/A YoY), and the FY2025 full-year result was $186000.0, changed N/A from the prior year.
- Capital Expenditures for Q3 2025 stood at $109000.0.
- The five-year high for Capital Expenditures was $109000.0 in Q3 2025, with the low at $109000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -63,220.27 |
| 10 | Climb Bio | 740.73 Mn | 740.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 109,000.00 |
| Sep 30, 2025 | 109,000.00 |